Arcticzymes Technologies Asa · OSL:AZT
Arcticzymes Technologies Asa — Q2 2021 Earnings Presentation
18 slides from Arcticzymes Technologies Asa's earnings presentation, 2021
Slide 1: ArcticZymes Technologies
A ArcticZymes Technologies
Slide 2: Agenda
Agenda 1 Highlights - Q2 2021 2 Business Update 3 Financials 4 Outlook 2021
Slide 3: Highlights
Highlights
Slide 4: Highlights Q2 2021
Highlights Q2 2021 Volatility in sales due to changing coronavirus environment Milestone achieved - Innovation review - Sales revenue sales revenues for Invest and expand performance last 12 months activities in 21.4 MNOK sales >100 MNOK Therapeutics Profitability New product continues Launched 6.0
Slide 5: Business Update
Business Update
Slide 6: Business Updates: Commercial Segment Sales
Business Updates Commercial Segment Sales Therapeutics Research & Diagnostics ✓ 26% quarterly reduction compared to Q2 2020 ✓ 41% quarterly reduction compared to Q2 2020 ✓ 40% contribution to total Q2 sales ✓ Research: 20% contribution to total Q2 sales ✓ Slow down due to several CMO´s prioritising
Slide 7: Business Updates: Coronavirus related sales
Business Updates Coronavirus related sales 21% contribution of total Q2 sales Q2 sales were expected to be lower than the extraordinary performances achieved during Q1 Majority of sales continues to be recurring business with several main customers Competitions in Asia between several customers Coro
Slide 8: Business Update: Innovation & Operations
Business Update Innovation & Operations Salt Active Nuclease HQ 2.0 (SAN HQ 2.0) launched Represents 2nd generation of the enzyme Optimised for wider compatibility with downstream biomanufacturing processes Increases commercial reach within viral vector market Viral vector biomanufacturing and utili
Slide 9: Business Update: Innovation Review
Business Update Innovation Review Molecular research and diagnostics Efforts are well underway to build a complete offering via organic and inorganic growth initiatives Therapeutics Current product offering and innovation efforts have focused on expanding SAN product line AZT plans to extend innovat
Slide 10: Financials
Financials
Slide 11: ArcticZymes Sales Q2 2021
ArcticZymes Sales Q2 2021 On same level as 4 of last 6 quarters Sales per segment Amounts in NOK 1.000' Sales decline of 36% compared to same 50 000 quarter last year 45 000 Therapeutics (SAN) Inventory was stocked up in Q2 2020 when 40 000 Research and Diagnostics the pandemic created its foothold
Slide 12: ArcticZymes Sales Q2 2021: Covid-19 impact
ArcticZymes Sales Q2 2021 Covid-19 impact is estimated at 21%of quarterly sales Estimated Coronavirus related sales Amounts in NOK 1.000' 18 000 16 000 14 000 12 000 10 000 8 000 6 000 4 000 2 000 - Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 12
Slide 13: 12 Month rolling average quarterly sales
12 Month rolling average quarterly sales Minor change in underlying sales development Amounts in NOK 1.000' 35 000 30 000 Sales development 25 000 Sales development ex Covid-19 20 000 15 000 10 000 5 000 - Q1 2018 Q2 2018 Q3 2018 Q4 2018 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 202
Slide 14: ArcticZymes Technologies: Sales and EBITDA
ArcticZymes Technologies Some headwind after a strong Q1 Amounts in NOK 1.000' 45 000 Sales 36% reduction in sales (MNOK 21.4 vs 33.4) 40 000 EBITDA EBITDA reduced by 16.5 MNOK (MNOK 6.0 vs 22.5) 35 000 30 000 Expenses increased by 5.7 MNOK 25 000 Increase in personnel as we investing in organic 20
Slide 15: Cash Flow
Cash Flow Continous to be positive Cash position 180 000 90 000 Net Cash Amounts in NOK 1.000' 160 000 Changes in Cash 80 000 140 000 70 000 120 000 60 000 Changes in Cash 100 000 50 000 Net Cash 80 000 40 000 60 000 30 000 40 000 20 000 20 000 10 000 0 0 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2
Slide 16: Outlook
Outlook
Slide 17: Outlook 2021
Outlook 2021 Financial goals Quarterly Rolling 12 Month Sales 140 Previous financial guidance given Dec 2019 with Last 12 month revenues (MNOK) Annual Revenue Target 2021 goal to reach 100 MNOK revenues by 2023 120 Previous Target 2023 Milestone achieved 100 >100 MNOK in revenues for the last 12-mon
Slide 18: Thank you Q&A Session
Thank you Q&A Session arcticzymes.com
ArcticZymes Technologies — Q2 2021 Earnings Presentation on 6ix